Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based Director operating in the Health Care space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Vincenzo Garzya
Patient Centricity Excellence Director of AstraZeneca
Follow Vincenzo Garzya:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
_______
Claus Bendtsen
Executive Director of AstraZeneca
Claus Bendtsen heads Quantitative Biology as part of Discovery Sciences within AstraZeneca. His department provides global support in areas of informatics, mathematical modelling, image analytics and non-clinical statistics. Prior to joining AstraZeneca he held positions at Novartis and Merck & Co. Earlier in his career he co-founded three start-ups and worked in academia. He holds a Ph.D. in applied mathematics and an MBA.
Follow Claus Bendtsen:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Ilaria Grizzi
Director, System Integration of Illumina
Follow Ilaria Grizzi:
About Illumina: Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Bernard Davitian
Vice President and Managing Director of Sanofi Ventures
Bernard Davitian has extensive experience in the life sciences and biotech industry, marked by a number of successful transactions involving financings and M&A. His track record includes, among others, the successful IPO of Transgene on the NASDAQ and Euronext in 1998 ($100 million raised) and the sale of Fovea Pharmaceuticals to Sanofi in 2009 in a €370 million cash transaction. Bernard joined Sanofi in 2010 as Vice President, Deputy of Global Head, Business Development Corporate Licenses and was promoted to Vice President and Managing Director of SGBV in 2012. Prior to Sanofi, Bernard was EVP & CFO of Fovea Pharmaceuticals, CEO of Neurotech Pharmaceuticals, and EVP & CFO of Transgene. Bernard began his career in the biotech sector by serving in various capacities at Institut Mérieux (now Sanofi Pasteur), including Corporate CFO. In addition to his SGBV-related Boards of Directors responsibilities, which include Immune Design, Proteostasis Therapeutics, Esperance Pharmaceuticals and Kahr Medical, Bernard also represents Sanofi on the Board of Directors of Warp Drive Bio. Bernard holds an MSc in Management from EM Lyon Business School (France). He is also a Certified Public Accountant (CPA) and holds an executive M.B.A. (AMP program) from Wharton Business School.
Follow Bernard Davitian:
About Good Eggs, Sanofi Ventures: Sanofi Ventures operates as the corporate venture capital arm of Sanofi.
Jason P. Hafler
Managing Director of Sanofi Ventures
Jason joined Sanofi-Genzyme BioVentures in 2014 with a background in early stage biotech investing and transactions. Prior to SGBV, Jason was the Director of Corporate Development at RaNA Therapeutics, LLC a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group and a Board Observer for several portfolio companies. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space. Jason currently serves on the Board of Trustees at the Buckingham Browne and Nichols school and on The Board of Directors of The Magdalene College Foundation. Jason holds a B.A. from Bowdoin College, and Ph.D. from the University of Cambridge.
Follow Jason P. Hafler:
About Buckingham Browne & Nichols School, Sanofi Ventures: Sanofi Ventures operates as the corporate venture capital arm of Sanofi.
Jay Bergeron
Director of Pfizer
Jay Bergeron is Director, Translational and Bioinformatics, at Pfizer and responsible for informatics support for Clinical Research and Precision Medicine.
Follow Jay Bergeron:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Julia Brosnan
Director, External Collaborations and Scientific Alliances of Pfizer
Follow Julia Brosnan:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
George Bashirians
Director, Diagnostics Lead of Pfizer
Follow George Bashirians:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Amir Zur
Sr. Director, Head of Products of Digital Health of Teva Pharmaceutical Industries
Amir Zur is a Sr. Director, Head of Products of Digital Health in Teva Pharmaceuticals, Mr. Zur leads the digital products roadmap, development life-cycle and quality to build Drug-Device Combination and Medical Device products to improve outcomes and treatments to patients. Previously at Teva, he led the teams who built a novel innovative product from scratch and established digital foundations, processes and transformation in the company. The product was recently approved by the FDA as the first of its kind in respiratory and in the entire Health industry. During his career Amir held vast leadership roles as an executive manager for more than 20 years in the digital industry both global large and small companies.
Follow Amir Zur:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Martin Jackson
Member of the Board of Directors of NaviHealth
Martin Jackson is the Board Director DispalyLink.Martin was, until September 2010, VP, Technology at Plastic Logic. Plastic Logic is using its proprietary technology leadership in plastic electronics to create a range of products enabling information access, organization, and consumption. At Plastic Logic Martin has responsible for the Cambridge technology centre, who have the core role in developing plastic electronics technology, and was actively involved in representing the company at numerous conferences and UK government initiatives. Prior to joining Plastic Logic in 2008 Martin was CTO at Artimi, a fabless semiconductor company that delivered high speed wireless connectivity in portable consumer devices. Prior to joining Artimi in 2006, Martin was CTO at Frontier Silicon, a fabless semiconductor company which pioneered digital broadcasting and achieved 70 percent market share.Prior to Frontier Silicon, he was CTO of leading DSL semiconductor company GlobespanVirata, which later merged into Conexant Corp. He began his work at Virata in 1994, when it was in a start-up phase and he served as VP engineering, Chief Technology Officer and a Board director. Martin was instrumental in the company’s merger with Globespan in 2001. Martin has co-founded four start-ups.He holds a First-Class Honours Degree with Distinction in Electronic Engineering from Cambridge University.
Follow Martin Jackson:
About 8power: NaviHealth partners with health plans, health systems and post-acute providers to manage the entire continuum of post-acute care.
Adam Sheriff
Senior Director, Clinical Drug Supply of Biogen Idec
Follow Adam Sheriff:
About Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Douglas Clark
Executive Director, Technology, Analytics and Data Insights of Biogen Idec
Follow Douglas Clark:
About Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Feng Gao
Director of Biogen Idec
Follow Feng Gao:
About Biogen Idec, Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Emma Wright
Senior Director, Manufacturing of Dicerna Pharmaceuticals
Follow Emma Wright:
About Dicerna Pharmaceuticals: Dicerna Pharmaceuticals is a biotechnology company with a focus on the development of innovative treatments for rare inherited diseases.
Chris Ballesteros
Senior Director, Business Development and Sales Enablement of OM1
Follow Chris Ballesteros:
About OM1: OM1 is a healthcare technology company that leverages real-world clinical data for medical research and personalized medicine.
Eric Boutin
Managing Director of dRx Capital
Eric Boutin was Founder | CEO of Evolve, acquired by HubSpot (NYSE: HUBS). He was Founder | CEO of Good Start Genetics, acquired by Invitae (NYSE: NVTA). He was Founder | VP of Flex Pharma, IPO (NASDAQ: FLKS). Eric was an EIR at Longwood Fund, and Founder of HBS Angels Boston. He holds a BA from Duke University, and an MBA from Harvard.
Follow Eric Boutin:
About dRx Capital: Novartis Digital Health Venture Capital
Roumen Radinov
Director, Process Chemistry of Alnylam Pharmaceuticals
Follow Roumen Radinov:
About Alnylam Pharmaceuticals, Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Kirk Brown
Director, CNS Early Development of Alnylam Pharmaceuticals
Follow Kirk Brown:
About Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Jennifer Hersch
Co-Founder & Director of Ethos
Follow Jennifer Hersch:
About Ethos: ETHOS is the ultimate yoga fitness hybrid experience with all one needs.
John Leonard
President , Chief Executive Officer & Member Board of Directors of Intellia Therapeutics
After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality. John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research. In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of QuintilesIMS (NYSE:Q) and Chimerix (Nasdaq:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.
Follow John Leonard:
About Intellia Therapeutics: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Girija Krishnamurthy
Executive Director Process Development of Amgen
Follow Girija Krishnamurthy:
About Amgen: Amgen is a biotechnology company that develops and manufactures human therapeutics for various illness and diseases.
Girija Krishnamurthy
Executive Director Process Development of Amgen
Follow Girija Krishnamurthy:
About Amgen: Amgen is a biotechnology company that develops and manufactures human therapeutics for various illness and diseases.
Nicholas Galakatos
Director of Praxis Precision Medicines
Nicholas Galakatos, PhD, has been Managing Director of Clarus Ventures since the firm’s inception in 2005. He has over 21 years of industry and investment experience in the healthcare sector, including being a General Partner in a healthcare venture capital firm since 2000. From 1997 to 2000, Nicholas Galakatos was Vice President of New Business at Millennium Pharmaceuticals (NASDAQ: MLNM) and a member of the Management Team. During that time he co-founded Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was Chairman. Prior to Millennium he was an Associate at Venrock Associates focusing on early stage biotechnology investments. Prior to Venrock he was Head of Molecular Biology Research at Novartis (formerly Ciba). Nicholas Galakatos earned his PhD in Organic Chemistry from MIT and performed his post-doctoral studies at Harvard Medical School. Nicholas Galakatos represents Clarus on the Board of Directors of Aerovance, Link Medicine, Nanostring, and Taligen. In addition, he is the Lead Director at Affymax (NASDAQ:AFFY) and is a Director of Aveo, and Portola. Previous directorships include Caliper (NASDAQ: CALP), Critical Therapeutics (NASDAQ: CRTX), Millennium Predictive Medicine (acquired by Millennium), Syrrx (acquired by Takeda), TransForm (acquired by J&J) and Hypnion (acquired by Eli Lilly).
Follow Nicholas Galakatos:
About Blackstone Group, Praxis Precision Medicines, The Blackstone Group Inc: Praxis Precision Medicines offers drug development services.
Alex Lagadinos
Associate Director, Corporate Development of Sarepta Therapeutics
Follow Alex Lagadinos:
About Sarepta Therapeutics: Sarepta Therapeutics focuses on the discovery and development of precision genetic medicine to treat rare diseases.
Richard Durbin
Informatics Director of Congenica
Richard is a Group Leader of the Human Genetics Programme at the Wellcome Trust Sanger Institute, a Fellow of the Royal Society, and a Member of EMBO. A pioneer in the industry, he has developed sequence data analysis tools that are now standards in the field. His current research focuses on human genetic variation by large scale genome-wide re-sequencing. Richard has led the international 1000 Genomes Project and the UK10K Genome Project, and has made significant contributions to the Ensembl resource for vertebrate genome annotation, and the TreeFam and Pfam databases.
Follow Richard Durbin:
About Congenica: Congenica is a biotechnology company that provides a diagnostic decision support platform.
Matthew Hurles
Scientific Director of Congenica
Matt is Senior Group Leader at the Wellcome Trust Sanger Institute and a leader in the Deciphering Developmental Disorders, 1000 Genomes and UK10K projects. He has pioneered the analysis of whole exomes in clinically relevant disorders that previously failed diagnostic methods, and has led an initiative to characterise structural variation in the human genome, and integrate this knowledge into disease and population genetic studies. Matt has been awarded the Balfour Lecture by the Genetics Society and the Crick Lecture prize for accomplishments in genetics by the Royal Society.
Follow Matthew Hurles:
About Congenica: Congenica is a biotechnology company that provides a diagnostic decision support platform.
Luke Hares
Technology Director of CMR Surgical
Before co-founding CMR he worked for product design companies in the UK and the US, where he worked on medical devices, robotics, ASIC developments and consumer products. Luke believes the best devices are created by combining a detailed knowledge of the unmet needs of the users with the creative application of a broad knowledge of available technology. Regular contact and interaction with the users of the product is essential for this process. Luke is responsible for leading the CMR technology team and has overall responsiblilty for the technology strategy of the company. He is accustomed to championing ideas, communicating technically complex ideas and designing and managing the development of complex systems.
Follow Luke Hares:
About CMR Surgical: CMR Surgical is developing the next-generation surgical robotic system for minimal access surgery.
David Brown
Co-Founder and Chairman of the Board of Directors of Healx
David Brown has 40 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for 8 years he led the team that invented and developed Viagra through to proof of clinical efficacy in male impotence. The drug is also marketed for treatment of pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have achieved sales of over $30 billion. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia. David subsequently co-founded antibody company Crescendo Biologics and serves on the boards of Healx Ltd (Chair), ProFactor Pharma Ltd (Chair) and Babraham Institute Enterprise Ltd (Chair). He is a Trustee (Director) of two charities, Antibiotic Research UK, dedicated to solving the looming problem of antibiotic resistance; and Friends of Manjushree Vidyapith School and Orphanage, a charity he co-founded in 2005 to help destitute orphans in South Tibet.
Follow David Brown:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Ian Roberts
Director of Therapeutic Technology of Healx
As senior investigator at the MRC Cancer Cell Unit, Cambridge, Ian lead the development of molecular cytogenetic and genomics approaches for the discovery of disease genes in small round blue cell tumours, and cervical carcinoma. During this time Ian developed algorithms for copy number imbalance analysis and integration with expression data using array based techniques. Following a move to industry, as Head of Informatics at Population Genetics Technologies Ltd Ian lead the development of Next Generation DNA Sequencing (NGS) variant discovery pipelines. Ian continued to develop NGS based variant discovery workflows as Senior Bioinformatician at 14M Genomics, before joining Healx in 2016.
Follow Ian Roberts:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Ahmed Alkhateeb
Associate Director of Business Development of Palleon Pharmaceuticals
A molecular biologist with experience in oncology, immunology, and entrepreneurship.
Follow Ahmed Alkhateeb:
About Palleon Pharmaceuticals: Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.
Shankar Balasubramian
Co-Founder and Director of Cambridge Epigenetix
Sir Shankar is Founder of two companies and the principal inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated to be worth >$30BN. Sir Shankar’s technology has made routine, accurate, low-cost sequencing of human genomes a reality, has revolutionised biology and accelerated the development of genomic personalised medicine. Sir Shankar is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge and Senior Group Leader at the Cancer Research UK Cambridge Institute. His awards include the Royal Medal (2018), the RoyalSociety Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of the Royal Society, the Academy of Medical Sciences and a member of EMBO.
Follow Shankar Balasubramian:
About Ahren Innovation Capital, Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Martin Murphy
Associate Director of Cambridge Epigenetix
Follow Martin Murphy:
About Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Alon Rivel
Director of Marketing of Outcomes4Me
Alon Rivel has been the Director of Global Sales & Marketing at Jack’d since March 2018. He first joined the company as the Brand Manager for Jack’d in October of 2016 and was then promoted to Director of Global Marketing in March of 2017. Alon heads the entire marketing, advertising sales, & creative departments for all brands and products within the Online Buddies umbrella internationally. Alon is a marketing & advertising media sales, buying, & planning professional with expertise in all aspects of digital, TV, mobile/tablet, radio, and print mediums. He has held roles in some of the biggest brands in the industry such as The New York Times, OMD, and Bloomberg. Alon was raised in NYC and brings that attitude and energy to the Online Buddies Boston office. He has an undergraduate degree with a double major in Communication & Legal Studies from the University of Massachusetts Amherst which he completed with highest honors. He is also IAB Certified in Digital Media Sales as of 2015.
Follow Alon Rivel:
About Outcomes4Me: Outcomes4Me is a developer of a free mobile app and platform to navigate cancer treatment and care.
Michael J. Ryan
Director of ClearPoint Neuro
Follow Michael J. Ryan:
About ClearPoint Neuro, Pulmonx: ClearPoint Neuro is a platform neuro company that enables therapy for neuro disorders with pinpoint accuracy.
Julian Gough
Co-Founder and Director of Genetrainer
Julian is a biotech entrepreneur and world expert in bioinformatics. He graduated his PhD in molecular biology from the University of Cambridge and was a research fellow at Stanford University. He is now a Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge and Professor of Bioinformatics at the University of Bristol. He has successfully started a number of biotech companies.
Follow Julian Gough:
About Genetrainer, Mogrify: Genetrainer is a website that provides a personalized fitness plan for users based on their genes.
Julie Legault
Executive Director, Founder of Amino Labs
Julie legault is the creative director, founder and ceo of amino labs inc, the company pioneering accessible bioengineering in the home and school. As a designer, julie works to make scientific and technological innovations approachable to the public, crafting experiences and products that invite culture shifts. She holds a master of art from the school of materials at the royal college of art (uk), degrees in both design technology and arts from concordia university (canada), and a masters of science from the mit media lab, massachusetts institute of technology(usa). She has taught at birmingham’s institute of art and design (uk) and worked with multi-nationals (aston martin, nokia, bombay sapphire,audi, etc), , museums, and pop stars like rihanna and imogen heap to develop smart materials, wearable technologies, and interactive art.
Follow Julie Legault:
About Amino Labs: Amino Labs is a biotechnology company that aims to make genetic engineering accessible to everyone.
Jenny Tillotson
Founder & Creative Director of eScent
Jenny Tillotson is the creator and driving force behind eScent, an enabling platform technology and delivery device that emits precise doses of fragrances at the right time, in the right place, depending on context. This is highly scalable technology for sensing and dispensing scent and liquids, providing a new sensory awareness with wide‐ranging applications in fashion, fragrances for luxury brands, wellbeing, digital health, AR/VR, retail, sports, entertainment, learning and adult industry. Jenny spent 14 years at Central Saint Martins, University of the Arts London developing her award-winning eScent research and was made a Reader in Sensory Fashion in 2013. More recently Jenny has moved to commercialise her research. She formed a company that works at the intersection of fashion, fragrance, smell and wearable technology, co-founded with Professor Andreas Manz, a pioneer of lab-on-a-chip and winner of the EU ‘lifetime achievement’ inventor award for patents on microchip technology for chemical applications. Jenny’s involvement over the past year has specifically been in the area of fine fragrance for the fashion industry and digital health for stress and sleep disorders with a particular focus on leveraging disparate data sources to discover more accurate health-related correlations. The company holds 4 granted patents and 1 pending patent that creates an exclusive market position on wearable sensory data collection related to the sense of smell, pharma and insect control. Jenny has a degree in Fashion Communication from Central Saint Martins and a PhD in interactive olfactory surfaces (Printed Textiles) from the Royal College of Art. She has been a Fellow of the of the Royal Society of Arts since 2009, a Fellow of the Winston Churchill Memorial Trust since 2013 and an Associate of the British Society of Perfumers since 2005. Jenny is also a Visiting Scholar in the Institute of Biotechnology at the University of Cambridge and a STEM Ambassador. Prior to her academic work she was a fashion stylist in the media and worked as a Sensory Designer for Charmed Technology (MIT Media Lab spin-off). She has exhibited internationally, published in science and design journals, consulted for NIKE, Unilever, INTEL, Qualcomm, Toyota and worked with Philips, Cambridge Consultants, The North Face, Adeline André and International Flavours & Fragrances.
Follow Jenny Tillotson:
About eScent, The Royal Society for the encouragement of Arts, Manufactures and Commerce (RSA): Wearable technology and sensory data collection for preventative healthcare.
Nawaz Khan
Research Director, Co-Founder of Discuva
Nawaz Khan is the VP Anti-infectives Research at Summit Therapeutics.
Follow Nawaz Khan:
About Discuva, Summit Therapeutics: Antibacterial discovery research has been driven, medically, commercially
Massimo Morin
Director Business Development and Partnerships of Doctor In Your Pocket
Follow Massimo Morin:
About Doctor In Your Pocket: Doctor in Your Pocket offers business and leisure travelers peace of mind when they travel internationally.
Anya Roy
Managing Director of Syrona Health
Anya Roy is the co-founder of Syrona Health.
Follow Anya Roy:
About Syrona Health: Syrona Health is a personalised digital health platform for Chronic Gynaecological/Uterine Conditions like Endometriosis, PCOS etc.
Irina Soltamova Solovyev
Director of Cambridge Oncometrix
Follow Irina Soltamova Solovyev:
About Cambridge Oncometrix: Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer.
Maxim Rossmann
Managing Director of Cambridge Oncometrix
Follow Maxim Rossmann:
About Cambridge Oncometrix, University of Cambridge: Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer.
Oriane Chausiaux
Founder Director – CSO, Serial Entrepreneur of Heartfelt Technologies
Follow Oriane Chausiaux:
About Heartfelt Technologies: Heartfelt Technologies are developing the only home-based heart failure monitor that does not require patient interaction or compliance.
Catherine Beech
Board of Directors of Exonate
Follow Catherine Beech:
About : Exonate is a biotech company spun out of the University of Nottingham that is focused on alternative splicing of (VEGF) in ophthalmology.
Joseph Coughlin
Founder and Director of MIT AgeLab
Follow Joseph Coughlin:
About MIT AgeLab: The MIT AgeLab was created in 1999 to invent new ideas and creatively translate technologies.
Andrew Southan
Chief Executive and Executive Director of Metrion Biosciences
Andy has over 25 years’ experience in life science research, including 14 years in the CRO sector. In 1991 he received his PhD in Pharmacology from the University of London (UK), investigating the effects of anaesthetics and high pressure on CNS potassium channels. Following a move to industry Andy worked as a brain slice electrophysiologist supporting ion channel-based CNS programmes at Wyeth (UK), before moving to Imperial College London where he published the first patch-clamp recordings from cerebellar inhibitory nerve terminals. At CeNeS Pharmaceuticals he performed CRO services (hERG, nAChR) and internal research on HCN and two-pore channels. He subsequently established the electrophysiology laboratory for Ionix Pharmaceuticals, a company focused on identifying novel pain therapeutics, where he worked on Nav, Cav and mechanosenstive ion channels. Before joining Metrion Andy spent 12 years in leadership roles at BioFocus and Charles River managing stand-alone projects, multi-year collaborations and fully integrated drug discovery programmes.
Follow Andrew Southan:
About Metrion Biosciences: Metrion Biosciences is a Contract Research Organization (CRO) that is located in the world renowned Cambridge biocluster.
David Alderson
Director of Cogentia Healthcare Consulting
David leads the Pricing and Strategic Market Access practice at Cogentia, a specialist market access and health economic consulting company. Over the last 25 years in the lifescienes industry, David has worked for GSK, Novartis, and Medimmune (Cambridge Antibody Technology), as well as Mundipharma and several market access consulting companies. Since 2009 David has been consulting in market access, leading projects and teams involved in payer research, pricing, strategic market access, value communication and proposition development, as well as advisory boards and training workshops. David has a MBA from Cranfield, and postgraduate Marketing Diploma (Chartered Institute of Marketing), and is also a Chartered Engineer (IMechE).
Follow David Alderson:
About Cogentia Healthcare Consulting: Cogentia Healthcare Consulting, provides market access skills, knowledge and expertise to the pharmaceutical, biotech and device industries.
Richard Saumarez
Director of Fen EP Limited
Follow Richard Saumarez:
About Fen EP Limited: Fen EP Limited is a developer of biomedical device created to prevent sudden cardiac death.
Richard Saumarez
Director of Fen EP Limited
Follow Richard Saumarez:
About Fen EP Limited: Fen EP Limited is a developer of biomedical device created to prevent sudden cardiac death.
